Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Scott J. Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier De Castro Carpeño, Adam Pluzanski, Marco A. Burgio, Marina Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wojcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie Brahmer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. Methods: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 studies. We did landmark analyses by response status at 6 months to determine post-landmark survival outcomes. We excluded patients who did not have a radiographic tumour assessment at 6 months. Safety analyses included all patients who received at least one dose of nivolumab. Findings: Across all four studies, 4-year overall survival with nivolumab was 14% (95% CI 11–17) for all patients (n=664), 19% (15–24) for those with at least 1% PD-L1 expression, and 11% (7–16) for those with less than 1% PD-L1 expression. In CheckMate 017 and 057, 4-year overall survival was 14% (95% CI 11–18) in patients treated with nivolumab, compared with 5% (3–7) in patients treated with docetaxel. Survival subsequent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for overall survival of 0·18 (95% 0·12–0·27) for nivolumab and 0·43 (0·29–0·65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0·52 (0·37–0·71) for nivolumab and 0·80 (0·61–1·04) for docetaxel. Long-term data did not show any new safety signals. Interpretation: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage. Funding: Bristol-Myers Squibb.

Original languageEnglish
Pages (from-to)1395-1408
Number of pages14
JournalThe Lancet Oncology
Volume20
Issue number10
DOIs
Publication statusPublished - Oct 2019

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Survival
nivolumab
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Antonia, S. J., Borghaei, H., Ramalingam, S. S., Horn, L., De Castro Carpeño, J., Pluzanski, A., ... Brahmer, J. (2019). Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. The Lancet Oncology, 20(10), 1395-1408. https://doi.org/10.1016/S1470-2045(19)30407-3

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer : a pooled analysis. / Antonia, Scott J.; Borghaei, Hossein; Ramalingam, Suresh S.; Horn, Leora; De Castro Carpeño, Javier; Pluzanski, Adam; Burgio, Marco A.; Garassino, Marina; Chow, Laura Q.M.; Gettinger, Scott; Crinò, Lucio; Planchard, David; Butts, Charles; Drilon, Alexander; Wojcik-Tomaszewska, Joanna; Otterson, Gregory A.; Agrawal, Shruti; Li, Ang; Penrod, John R.; Brahmer, Julie.

In: The Lancet Oncology, Vol. 20, No. 10, 10.2019, p. 1395-1408.

Research output: Contribution to journalArticle

Antonia, SJ, Borghaei, H, Ramalingam, SS, Horn, L, De Castro Carpeño, J, Pluzanski, A, Burgio, MA, Garassino, M, Chow, LQM, Gettinger, S, Crinò, L, Planchard, D, Butts, C, Drilon, A, Wojcik-Tomaszewska, J, Otterson, GA, Agrawal, S, Li, A, Penrod, JR & Brahmer, J 2019, 'Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis', The Lancet Oncology, vol. 20, no. 10, pp. 1395-1408. https://doi.org/10.1016/S1470-2045(19)30407-3
Antonia, Scott J. ; Borghaei, Hossein ; Ramalingam, Suresh S. ; Horn, Leora ; De Castro Carpeño, Javier ; Pluzanski, Adam ; Burgio, Marco A. ; Garassino, Marina ; Chow, Laura Q.M. ; Gettinger, Scott ; Crinò, Lucio ; Planchard, David ; Butts, Charles ; Drilon, Alexander ; Wojcik-Tomaszewska, Joanna ; Otterson, Gregory A. ; Agrawal, Shruti ; Li, Ang ; Penrod, John R. ; Brahmer, Julie. / Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer : a pooled analysis. In: The Lancet Oncology. 2019 ; Vol. 20, No. 10. pp. 1395-1408.
@article{2e50cd1f518e448d9468c9f62775ab2f,
title = "Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis",
abstract = "Background: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. Methods: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 studies. We did landmark analyses by response status at 6 months to determine post-landmark survival outcomes. We excluded patients who did not have a radiographic tumour assessment at 6 months. Safety analyses included all patients who received at least one dose of nivolumab. Findings: Across all four studies, 4-year overall survival with nivolumab was 14{\%} (95{\%} CI 11–17) for all patients (n=664), 19{\%} (15–24) for those with at least 1{\%} PD-L1 expression, and 11{\%} (7–16) for those with less than 1{\%} PD-L1 expression. In CheckMate 017 and 057, 4-year overall survival was 14{\%} (95{\%} CI 11–18) in patients treated with nivolumab, compared with 5{\%} (3–7) in patients treated with docetaxel. Survival subsequent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for overall survival of 0·18 (95{\%} 0·12–0·27) for nivolumab and 0·43 (0·29–0·65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0·52 (0·37–0·71) for nivolumab and 0·80 (0·61–1·04) for docetaxel. Long-term data did not show any new safety signals. Interpretation: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage. Funding: Bristol-Myers Squibb.",
author = "Antonia, {Scott J.} and Hossein Borghaei and Ramalingam, {Suresh S.} and Leora Horn and {De Castro Carpe{\~n}o}, Javier and Adam Pluzanski and Burgio, {Marco A.} and Marina Garassino and Chow, {Laura Q.M.} and Scott Gettinger and Lucio Crin{\`o} and David Planchard and Charles Butts and Alexander Drilon and Joanna Wojcik-Tomaszewska and Otterson, {Gregory A.} and Shruti Agrawal and Ang Li and Penrod, {John R.} and Julie Brahmer",
year = "2019",
month = "10",
doi = "10.1016/S1470-2045(19)30407-3",
language = "English",
volume = "20",
pages = "1395--1408",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer

T2 - a pooled analysis

AU - Antonia, Scott J.

AU - Borghaei, Hossein

AU - Ramalingam, Suresh S.

AU - Horn, Leora

AU - De Castro Carpeño, Javier

AU - Pluzanski, Adam

AU - Burgio, Marco A.

AU - Garassino, Marina

AU - Chow, Laura Q.M.

AU - Gettinger, Scott

AU - Crinò, Lucio

AU - Planchard, David

AU - Butts, Charles

AU - Drilon, Alexander

AU - Wojcik-Tomaszewska, Joanna

AU - Otterson, Gregory A.

AU - Agrawal, Shruti

AU - Li, Ang

AU - Penrod, John R.

AU - Brahmer, Julie

PY - 2019/10

Y1 - 2019/10

N2 - Background: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. Methods: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 studies. We did landmark analyses by response status at 6 months to determine post-landmark survival outcomes. We excluded patients who did not have a radiographic tumour assessment at 6 months. Safety analyses included all patients who received at least one dose of nivolumab. Findings: Across all four studies, 4-year overall survival with nivolumab was 14% (95% CI 11–17) for all patients (n=664), 19% (15–24) for those with at least 1% PD-L1 expression, and 11% (7–16) for those with less than 1% PD-L1 expression. In CheckMate 017 and 057, 4-year overall survival was 14% (95% CI 11–18) in patients treated with nivolumab, compared with 5% (3–7) in patients treated with docetaxel. Survival subsequent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for overall survival of 0·18 (95% 0·12–0·27) for nivolumab and 0·43 (0·29–0·65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0·52 (0·37–0·71) for nivolumab and 0·80 (0·61–1·04) for docetaxel. Long-term data did not show any new safety signals. Interpretation: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage. Funding: Bristol-Myers Squibb.

AB - Background: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. Methods: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 studies. We did landmark analyses by response status at 6 months to determine post-landmark survival outcomes. We excluded patients who did not have a radiographic tumour assessment at 6 months. Safety analyses included all patients who received at least one dose of nivolumab. Findings: Across all four studies, 4-year overall survival with nivolumab was 14% (95% CI 11–17) for all patients (n=664), 19% (15–24) for those with at least 1% PD-L1 expression, and 11% (7–16) for those with less than 1% PD-L1 expression. In CheckMate 017 and 057, 4-year overall survival was 14% (95% CI 11–18) in patients treated with nivolumab, compared with 5% (3–7) in patients treated with docetaxel. Survival subsequent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for overall survival of 0·18 (95% 0·12–0·27) for nivolumab and 0·43 (0·29–0·65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0·52 (0·37–0·71) for nivolumab and 0·80 (0·61–1·04) for docetaxel. Long-term data did not show any new safety signals. Interpretation: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage. Funding: Bristol-Myers Squibb.

UR - http://www.scopus.com/inward/record.url?scp=85072654087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072654087&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30407-3

DO - 10.1016/S1470-2045(19)30407-3

M3 - Article

C2 - 31422028

AN - SCOPUS:85072654087

VL - 20

SP - 1395

EP - 1408

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -